Please assess the completion status of the following clinical trial:

Trial Title: Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18-70 years~* Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1~* On a stable (\> 3 months prior to Screening Visit 1) treatment regimen of metformin monotherapy;~* Fasting plasma glucose \< 240 mg/dL at Screening Visit 1~* HbA1c ≥ 7% and ≤ 10% at Screening Visit 1~Exclusion Criteria:~* Prior treatment with exenatide~* Treatment with any of the following antidiabetic agents within 3 months prior to Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin (injected or inhaled)~* History of type 1 diabetes and/or history of diabetic ketoacidosis~* Body mass index ≥ 40 kg/m2;~* History of organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ITCA 650 20 mcg/day (Type: EXPERIMENTAL): None
- ITCA 650 40 mcg/day (Type: EXPERIMENTAL): None
- Exenatide Injection (Type: ACTIVE_COMPARATOR): None
- ITCA 650 20/20 (Type: EXPERIMENTAL): None
- ITCA 650 20/60 (Type: EXPERIMENTAL): None
- ITCA 650 40/40 (Type: EXPERIMENTAL): None
- ITCA 650 40/80 (Type: EXPERIMENTAL): None
- Ex Inj/ITCA 650 40 (Type: EXPERIMENTAL): None
- Ex Inj/ITCA 650 60 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).